Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

The impact of baseline covariates on the efficiency of statistical analyses of crossover designs.

Yan Z.

Stat Med. 2013 Mar 15;32(6):956-63. doi: 10.1002/sim.5579. Epub 2012 Aug 18.

PMID:
22903413
2.

On the role of Baseline measurements for crossover designs under the self and mixed carryover effects model.

Liang Y, Carriere KC.

Biometrics. 2010 Mar;66(1):140-8. doi: 10.1111/j.1541-0420.2009.01229.x. Epub 2009 May 7.

PMID:
19432775
3.

Handling of baseline measurements in the analysis of crossover trials.

Chen X, Meng Z, Zhang J.

Stat Med. 2012 Jul 30;31(17):1791-803. doi: 10.1002/sim.4466. Epub 2012 Jun 19.

PMID:
22715129
4.

Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.

Yan Z, Hosmane B, Locke C.

J Biopharm Stat. 2013;23(4):804-17. doi: 10.1080/10543406.2013.792827.

PMID:
23786490
5.

Sample size calculation for the Power Model for dose proportionality studies.

Sethuraman VS, Leonov S, Squassante L, Mitchell TR, Hale MD.

Pharm Stat. 2007 Jan-Mar;6(1):35-41.

PMID:
17323313
6.

Cost-efficient higher-order crossover designs in comparative bioavailability studies.

Zhou J, Yuan Y, Reynolds R, Raber S, Li Y.

Clin Pharmacokinet. 2006;45(6):623-32.

PMID:
16719543
7.

Cluster-crossover design: a method for limiting clusters level effect in community-intervention studies.

Parienti JJ, Kuss O.

Contemp Clin Trials. 2007 May;28(3):316-23. Epub 2006 Oct 6.

PMID:
17110172
8.
9.

Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.

Takada M, Sozu T, Sato T.

Pharm Stat. 2015 May-Jun;14(3):198-204. doi: 10.1002/pst.1674. Epub 2015 Mar 16.

PMID:
25776032
10.

CrossOver: an algorithm for the construction of efficient cross-over designs.

John JA, Russell KG, Whitaker D.

Stat Med. 2004 Sep 15;23(17):2645-58.

PMID:
15316948
11.

A recommended analysis for 2 × 2 crossover trials with baseline measurements.

Mehrotra DV.

Pharm Stat. 2014 Nov-Dec;13(6):376-87. doi: 10.1002/pst.1638. Epub 2014 Sep 17.

PMID:
25230245
12.

Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs'.

Yan Z.

Stat Med. 2013 Dec 30;32(30):5484-6. doi: 10.1002/sim.5995. No abstract available.

PMID:
24302283
13.

An efficient analysis of covariance model for crossover thorough QT studies with period-specific baseline days.

Lu K.

Pharm Stat. 2013 Jul-Aug;12(4):192-200. doi: 10.1002/pst.1569. Epub 2013 Apr 29.

PMID:
23625584
14.

The use of baseline covariates in crossover studies.

Kenward MG, Roger JH.

Biostatistics. 2010 Jan;11(1):1-17. doi: 10.1093/biostatistics/kxp046. Epub 2009 Nov 13.

PMID:
19915170
15.

Authors' reply to Comments on 'Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs".

Jaki T, Pallmann P, Wolfsegger MJ.

Stat Med. 2013 Dec 30;32(30):5487-8. doi: 10.1002/sim.6000. No abstract available.

PMID:
24302284
16.

HGLM versus conditional estimators for the analysis of clustered binary data.

Kang W, Lee MS, Lee Y.

Stat Med. 2005 Mar 15;24(5):741-52.

PMID:
15696505
17.

Tests for inter-subject and total variabilities under crossover designs.

Lee Y, Shao J, Chow SC, Wang H.

J Biopharm Stat. 2002 Nov;12(4):503-34.

PMID:
12477072
18.

Bayesian analyses of two-treatment crossover studies.

Grieve AP.

Stat Methods Med Res. 1994 Dec;3(4):407-29. Review.

PMID:
7889229
19.

Efficiency of balanced treatment allocation for survival analysis.

Kalish LA, Harrington DP.

Biometrics. 1988 Sep;44(3):815-21.

PMID:
3203130
20.

Optimal crossover designs for logistic regression models in pharmacodynamics.

Waterhouse TH, Eccleston JA, Duffull SB.

J Biopharm Stat. 2006;16(6):881-94.

PMID:
17146986

Supplemental Content

Support Center